Prashant Agrawal

Volunteer and Community Engagement

• Volunteer Member, Red Cross New Zealand. Participated in a clothing drive to support underprivileged communities.
• Member, New Zealand Institute of International Affairs (NZIIA). Participated in a speaker event, "A Conversation with the U.S." Ambassador Udall's banner artwork.
• Peer Reviewer, National and International Journals. Reviewed multiple articles for publication in peer-reviewed journals.

Therapy Area: Allergy and Pain; KOLs: Otolaryngologists (ear, nose, and throat specialists), pediatricians, dermatologists, allergists, and pulmonologists.

Molecules/brands - Main - Fexofenadine HCl (Allegra)

Other: Paracetamol + ibuprofen FDC (Combiflam), pheniramine maleate (Avil).

• Strategic Medical Leadership: Led medical strategy for top-selling brands, including Allegra (INR 3,000M), Avil, and Combiflam, developing targeted medical and digital engagement plans based on the latest scientific data and product differentiation.
• Business Transformation: Played a key role in establishing Sanofi Consumer Healthcare as a separate business entity, contributing to strategic and operational frameworks.
• Medical Collaborations: Spearheaded partnerships with professional medical societies (IAP, ICS, IOA), government bodies, and private healthcare systems, ensuring impactful medical presentations and advocacy.
• Regulatory compliance and approvals: dossier preparation, submissions, and compliance with local/FDA guidelines.
• Team representation: at national, international, internal, and external events, conferences (Asia-Pacific meetings, World Allergy Association annual event).
• Scientific Engagement and Education:
• Successfully managed two large-scale international speaker events across multiple cities and several virtual CMEs, enhancing HCP education (approximately 10,000 participants).
• Led the development of local scientific publications (RWE), ensuring alignment with Sanofi’s global medical strategy and scientific credibility.
• Cross-Functional Excellence: Oversaw medical operations, including internal/external communications, periodic newsletters, and seamless coordination with marketing teams to drive brand success.
• Training & Leadership Development: Contributed to cross-functional projects, including slide deck development, training programs, and executive presentations.
• Awards & Recognition: Honored by Sanofi Asia Leadership for the innovative "Pause Atopic March 3.0" project, engaging over 300 HCPs, and driving impactful healthcare solutions.

Therapy area- Respiratory and Immunology; KOLs Pulmonologists -, Allergologists and Otolaryngologists (Ear, Nose and Throat specialist), Paediatricians.

Molecules/brands - Measure - Benralizumab, Tezepeluzumab, Synagis,

Other- Symbicort Turbohaler

• Strategic Medical Leadership: Designed and executed medical initiatives for three new product launches in collaboration with national and international medical societies, driving disease awareness among HCPs, policymakers, and patients.
• Key Opinion Leader (KOL) Engagement: Developed a robust professional network with leading national and international pulmonologists, leveraging insights to shape clinical practice and internal communication strategies.
• Cross-functional collaboration: Partnered with marketing, sales, regulatory, drug safety, clinical trials, and market access teams to introduce innovative pulmonology therapies and ensure seamless execution of strategic projects.
• Digital & Patient-Centric Initiatives:
• Led award-winning omnichannel campaigns, including the IOptforHealthyLungs awareness program and Asthma Advances emailer to 3,000 HCPs (40%+ open rate).
• Spearheaded COPD Triple Combination (ICS/LABA/LAMA) with 8 top KOLs and the first-ever Patient Advisory Board with an outcome-driven RACI matrix.
• Organized internal engagement initiatives, such as the Healthy Lungs Campaign and patient education activities (FB Live, VOH digital panels).
• Supported the formation of five fully working precision clinics at known corporate hospitals for early diagnosis and management of severe asthma.
• Scientific and Medical Excellence:
• Led a Phase IV Real-World Evidence Study as a principal scientist to generate critical clinical data on benralizumab.
• RWE-prepared XALOC-2: Protocol for the international RWE project.
• Build a refer-ID project for the right referrals of severe asthma patients to tertiary centers.
• Selected as MSL Global Ambassador at the global conference ERS 2021 and a core team member for the I-Buddy International Project.
• Served as a global facilitator for Kate & Kath, Digital Champion (India), and Patient-Centric Activity Champion.
• Awards & Recognition:
• Medical & Regulatory Annual Award – Best Innovative Project (Asthma Advances)
• Shikhar Award 2022 – Accelerating Innovative Science and Solutions in Market Access.
• India-Sweden Healthcare Innovation Challenge 2.0 Winner.
• iBuddy Program Recognition

Therapeutic Expertise & KOL Engagement: Collaborated with leading national and international cardiologists to identify unmet clinical needs and facilitate scientific dissemination among physicians.

Strategic Product Launches: Provided medical and marketing support for the launch of biosimilar Tenecteplase (TNK-TPA), the latest antiplatelet agents, Ivabradine, and other CVS-branded generics.

Cross-Functional Leadership:

Led internal stakeholder collaborations to drive successful launches of generic Ticagrelor and Ivabradine.

I organized three high-impact advisory boards, engaging top key opinion leaders (KOLs) across multiple specialties.

Project Management and Innovation:

Independently managed an international R&D project focused on innovative product development within Emcure Pharmaceuticals, delivering results within a short timeframe.

• Medical Education & Training: Conducted lectures, practical sessions, and case-based discussions for medical and pharmacy students, focusing on clinical pharmacology, therapeutics, and drug safety.
• Research & Publications: Engaged in clinical research, pharmacovigilance studies, and drug utilization reviews, contributing to peer-reviewed publications and conference presentations.
• Regulatory & Ethical Compliance: Applied Good Clinical Practice (GCP) guidelines, regulatory standards, and Health Canada (HC)/FDA-aligned ethical protocols in research and clinical trials.
• Cross-Disciplinary Collaboration: Worked with clinicians, pharmacists, and researchers to bridge the gap between academic pharmacology and real-world clinical application.

• Acute Patient Management: Provided critical emergency care, managing trauma, cardiac emergencies, poisoning, and acute medical conditions in a high-volume hospital setting.
• Clinical Decision-Making & Drug Administration: Prescribed and administered life-saving medications, including thrombolytics, analgesics, antibiotics, and emergency cardiovascular drugs, ensuring adherence to clinical pharmacology principles.
• Interdisciplinary Collaboration: Worked closely with emergency physicians, intensivists, and paramedical staff to stabilize patients and optimize treatment plans.

• Healthcare Leadership & Team Management: Led a multidisciplinary team of 10-15 medical and paramedical staff, overseeing outpatient care, preventive health programs, and rural medical camps for underserved tribal communities.
• Public Health & Community Outreach: Organized and executed health awareness initiatives, vaccination drives, and primary care services, ensuring improved healthcare access in remote regions.
• Regulatory and Administrative Oversight:
• Managed regulatory documentation, compliance with public health policies, and reporting to local health authorities.
• Collaborated with government agencies and local governing bodies to enhance healthcare delivery and secure resources for community health programs.